Neurogene (NGNE) EBIT Margin (2018 - 2024)
Neurogene (NGNE) posted EBIT Margin of 2176.65% for Q2 2024, down 36472.5% on a QoQ basis from 5.95% in Q3 2019.
Neurogene (NGNE) EBIT Margin (2018 - 2024) Analysis & Trends
Neurogene's EBIT Margin history runs 3 years deep, the most recent figure standing at 2176.65% for Q2 2024.
- Quarterly EBIT Margin changed N/A year-over-year to 2176.65% in Q2 2024, while the trailing twelve-month figure through Jun 2025 was 10345.08% (down 290022.0% YoY) and the FY2024 annual result came in at 8930.27%, changed N/A from the prior year.
- EBIT Margin was 2176.65% for Q2 2024 at Neurogene, down from 5.95% in the prior quarter.
- Across five years, EBIT Margin topped out at 2176.65% in Q2 2024 and bottomed at 2176.65% in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Neurogene | 776.69 Mn | 776.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -2,176.65% |
| Sep 30, 2019 | -5.95% |
| Jun 30, 2018 | 10.76% |